Eledon Pharmaceuticals (ELDN) Projected to Post Quarterly Earnings on Monday

Key Points

• Eledon Pharmaceuticals is set to release its Q2 2025 earnings on August 18th, with analysts expecting a loss of ($0.23) per share for the quarter.
• The company reported a loss of ($0.08) per share in its last earnings announcement, surpassing estimates by $0.20.
• Eledon Pharmaceuticals' stock is currently trading down 1.1% at $2.71, with several brokerages giving mixed ratings, including upgrades to "buy" from HC Wainwright and Craig Hallum.

Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Monday, August 18th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter.

Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.28) by $0.20. On average, analysts expect Eledon Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Eledon Pharmaceuticals Trading Down 0.2%

Eledon Pharmaceuticals stock traded down $0.01 during mid-day trading on Thursday, reaching $2.60. The company had a trading volume of 481,518 shares, compared to its average volume of 411,266. Eledon Pharmaceuticals has a fifty-two week low of $2.38 and a fifty-two week high of $5.54. The company has a market cap of $155.39 million, a P/E ratio of -1.24 and a beta of -0.15. The business has a fifty day simple moving average of $3.13 and a 200 day simple moving average of $3.41.

Wall Street Analyst Weigh In

ELDN has been the subject of several recent research reports. HC Wainwright raised shares of Eledon Pharmaceuticals to a "buy" rating and set a $9.00 target price for the company in a research report on Wednesday, June 18th. Wall Street Zen cut shares of Eledon Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday, June 6th. Finally, Craig Hallum started coverage on shares of Eledon Pharmaceuticals in a report on Friday, July 25th. They set a "buy" rating and a $12.00 price target on the stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its stake in Eledon Pharmaceuticals by 107.6% in the second quarter. Geode Capital Management LLC now owns 1,383,940 shares of the company's stock valued at $3,751,000 after acquiring an additional 717,223 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Eledon Pharmaceuticals by 78.2% in the first quarter. Goldman Sachs Group Inc. now owns 258,106 shares of the company's stock valued at $875,000 after acquiring an additional 113,261 shares during the last quarter. Jane Street Group LLC boosted its stake in Eledon Pharmaceuticals by 83.7% in the first quarter. Jane Street Group LLC now owns 224,600 shares of the company's stock valued at $761,000 after acquiring an additional 102,325 shares during the last quarter. Marshall Wace LLP boosted its stake in Eledon Pharmaceuticals by 393.6% in the second quarter. Marshall Wace LLP now owns 94,772 shares of the company's stock valued at $257,000 after acquiring an additional 75,572 shares during the last quarter. Finally, New York State Common Retirement Fund purchased a new position in Eledon Pharmaceuticals in the second quarter valued at about $99,000. 56.77% of the stock is currently owned by hedge funds and other institutional investors.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).